A monoclonal antibody targeting Siglec-15 (NC318) has shown promising results in a variety tumor model in mice [10], and there is an ongoing phase I/II clinical trial (NCT03665285) targeting advanced or metastatic solid tumors, which has shown responses in patients suffering from non-small-cell lung cancer who were unresponsive to PD-1 inhibitors. Here, PDCD1 is linked to neoplasm.